Zyvox® Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008

Diagnostic Microbiology and Infectious Disease

Volumn 65, Issue 4, 2009, Pages 404-413

  Jones, Ronald N ^a,b   Ross, James E ^a   Bell, Jan M ^c   Utsuki, Uchino ^d   Fumiaki, Ikeda ^d   Kobayashi, Intetsu ^e   Turnidge, John D ^c  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^d TOHO UNIVERSITY SAKURA MEDICAL CENTER   (Japan)

^e LSI MEDIENCE CORPORATION   (Japan)

Author keywords

cfr; Linezolid; Oxazolidinones; Resistance; Surveillance; Target mutations; ZAAPS Program

Indexed keywords

AMPICILLIN; CEFTRIAXONE; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DOXYCYCLINE; ERYTHROMYCIN; GENTAMICIN; GUANOSINE; LEVOFLOXACIN; LINEZOLID; OXACILLIN; OXAZOLIDINONE DERIVATIVE; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; RIBOSOME RNA; RNA 23S; STREPTOMYCIN; TEICOPLANIN; TETRACYCLINE; THYMINE; VANCOMYCIN; ACETAMIDE DERIVATIVE; ANTIINFECTIVE AGENT; BACTERIAL RNA;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; ASIA; BACTERIAL STRAIN; BACTERIUM ISOLATE; BETA HEMOLYTIC STREPTOCOCCUS; BROTH DILUTION; CANADA; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MONITORING; DRUG POTENCY; DRUG SURVEILLANCE PROGRAM; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; EUROPE; GENE MUTATION; GEOGRAPHIC DISTRIBUTION; GRAM POSITIVE BACTERIUM; HEALTH PROGRAM; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SOUTH AND CENTRAL AMERICA; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS PNEUMONIAE; CLINICAL TRIAL; DRUG EFFECT; GENETICS; GRAM POSITIVE INFECTION; HUMAN; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MULTICENTER STUDY; POINT MUTATION; PREVALENCE;

ACETAMIDES; ANTI-BACTERIAL AGENTS; ASIA; CANADA; DRUG RESISTANCE, BACTERIAL; EUROPE; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; LATIN AMERICA; MICROBIAL SENSITIVITY TESTS; OXAZOLIDINONES; POINT MUTATION; PREVALENCE; RNA, BACTERIAL; RNA, RIBOSOMAL, 23S;

EID: 71549129290     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2009.10.001     Document Type: Article

References (55)

1. Anderegg T.R., Sader H.S., Fritsche T.R., Ross J.E., and Jones R.N. Trends in linezolid susceptibility patterns: report from the 2002-2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program. Int. J. Antimicrob. Agents 26 (2005) 13-21
2. Auckland C., Teare L., Cooke F., Kaufmann M.E., Warner M., Jones G., Bamford K., Ayles H., and Johnson A.P. Linezolid-resistant enterococci: report of the first isolates in the United Kingdom. J. Antimicrob. Chemother. 50 (2002) 743-746
3. Ballow C.H., Biedenbach D.J., Rossi F., and Jones R.N. Multicenter assessment of the linezolid spectrum and activity using the disk diffusion and Etest methods: report of the Zyvox® Antimicrobial Potency Study in Latin America (LA-ZAPS). Braz. J. Infect. Dis. 6 (2002) 100-109
4. Ballow C.H., Jones R.N., and Biedenbach D.J. A multicenter evaluation of linezolid antimicrobial activity in North America. Diagn. Microbiol. Infect Dis. 43 (2002) 75-83
5. Bell J.M., Turnidge J.D., Ballow C.H., and Jones R.N. Multicentre evaluation of the in vitro activity of linezolid in the Western Pacific. J. Antimicrob. Chemother. 51 (2003) 339-345
6. Bolmstrom A., Ballow C.H., Qwarnstrom A., Biedenbach D.J., and Jones R.N. Multicentre assessment of linezolid antimicrobial activity and spectrum in Europe: report from the Zyvox antimicrobial potency study (ZAPS-Europe). Clin. Microbiol. Infect. 8 (2002) 791-800
7. Brickner S.J., Hutchinson D.K., Barbachyn M.R., Manninen P.R., Ulanowicz D.A., Garmon S.A., Grega K.C., Hendges S.K., Toops D.S., Ford C.W., and Zurenko G.E. Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant Gram-positive bacterial infections. J. Med. Chem. 39 (1996) 673-679
8. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial disk susceptibility tests; approved standard - tenth edition, M02-A10 (2009), CLSI, Wayne, PA
9. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard - eight edition, M07-A8 (2009), CLSI, Wayne, PA
10. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: 19th informational supplement (M100-S19) (2009), CLSI, Wayne, PA
11. Diekema D.J., and Jones R.N. Oxazolidinone antibiotics. Lancet 358 (2001) 1975-1982
12. French G. Safety and tolerability of linezolid. J. Antimicrob. Chemother. 51 Suppl 2 (2003) ii45-ii53
13. Gales A.C., Sader H.S., Andrade S.S., Lutz L., Machado A., and Barth A.L. Emergence of linezolid-resistant Staphylococcus aureus during treatment of pulmonary infection in a patient with cystic fibrosis. Int. J. Antimicrob. Agents 27 (2006) 300-302
14. Gemmell C.G. Susceptibility of a variety of clinical isolates to linezolid: a European inter-country comparison. J. Antimicrob. Chemother. 48 (2001) 47-52
15. Gonzales R.D., Schreckenberger P.C., Graham M.B., Kelkar S., DenBesten K., and Quinn J.P. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 357 (2001) 1179
16. Henwood C.J., Livermore D.M., Johnson A.P., James D., Warner M., and Gardiner A. Susceptibility of Gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. The Linezolid Study Group. J. Antimicrob. Chemother. 46 (2000) 931-940
17. Herrero I.A., Issa N.C., and Patel R. Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium. N. Engl. J. Med. 346 (2002) 867-869
18. Jones R.N., Johnson D.M., and Erwin M.E. In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones. Antimicrob. Agents Chemother. 40 (1996) 720-726
19. Jones R.N., Ballow C.H., and Biedenbach D.J. Multi-laboratory assessment of the linezolid spectrum of activity using the Kirby-Bauer disk diffusion method: report of the Zyvox Antimicrobial Potency Study (ZAPS) in the United States. Diagn. Microbiol. Infect. Dis. 40 (2001) 59-66
20. Jones R.N., Della-Latta P., Lee L.V., and Biedenbach D.J. Linezolid-resistant Enterococcus faecium isolated from a patient without prior exposure to an oxazolidinone: report from the SENTRY Antimicrobial Surveillance Program. Diagn. Microbiol. Infect Dis. 42 (2002) 137-139
21. Jones R.N., Ross J.E., Fritsche T.R., and Sader H.S. Oxazolidinone susceptibility patterns in 2004: report from the Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations. J. Antimicrob. Chemother. 57 (2006) 279-287
22. Jones R.N., Fritsche T.R., Sader H.S., and Ross J.E. Zyvox® Annual Appraisal of Potency and Spectrum Program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries. Diagn. Microbiol. Infect Dis. 59 (2007) 199-209
23. Jones R.N., Stilwell M.G., Hogan P.A., and Sheehan D.J. Activity of linezolid against 3,251 strains of uncommonly isolated gram-positive organisms: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob. Agents Chemother. 51 (2007) 1491-1493
24. Jones R.N., Ross J.E., Castanheira M., and Mendes R.E. United States resistance surveillance results for linezolid (LEADER Program for 2007). Diagn. Microbiol. Infect. Dis. 62 (2008) 416-426
25. Jones R.N., Kohno S., Ono Y., Ross J.E., and Yanagihara K. ZAAPS International Surveillance Program (2007) for linezolid resistance: results from 5591 Gram-positive clinical isolates in 23 countries. Diagn. Microbiol. Infect. Dis. 64 (2009) 191-201
26. Kollef M.H., Rello J., Cammarata S.K., Croos-Dabrera R.V., and Wunderink R.G. Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med. 30 (2004) 388-394
27. Marshall S.H., Donskey C.J., Hutton-Thomas R., Salata R.A., and Rice L.B. Gene dosage and linezolid resistance in Enterococcus faecium and Enterococcus faecalis. Antimicrob. Agents Chemother. 46 (2002) 3334-3336
28. McCollum M., Sorensen S.V., and Liu L.Z. A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft-tissue infections caused by suspected or confirmed methicillin-resistant Staphylococcus aureus in elderly US patients. Clin. Ther. 29 (2007) 469-477
29. McKinnon P.S., Carter C.T., Girase P.G., Liu L.Z., and Carmeli Y. The economic effect of oral linezolid versus intravenous vancomycin in the outpatient setting: the payer perspective. Manag. Care Interface 20 (2007) 23-34
30. Meka V.G., and Gold H.S. Antimicrobial resistance to linezolid. Clin. Infect. Dis. 39 (2004) 1010-1015
31. Mendes R.E., Deshpande L.M., Castanheira M., DiPersio J., Saubolle M.A., and Jones R.N. First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States. Antimicrob. Agents Chemother. 52 (2008) 2244-2246
32. Moellering R.C. Linezolid: the first oxazolidinone antimicrobial. Ann. Intern. Med. 138 (2003) 135-142
33. Mouton J.W., and Jansz A.R. The DUEL study: a multi-center in vitro evaluation of linezolid compared with other antibiotics in the Netherlands. Clin. Microbiol. Infect. 7 (2001) 486-491
34. Mutnick A.H., Biedenbach D.J., Turnidge J.D., and Jones R.N. Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998-2000. Diagn. Microbiol. Infect. Dis. 43 (2002) 65-73
35. Mutnick A.H., Enne V., and Jones R.N. Linezolid resistance since 2001: SENTRY Antimicrobial Surveillance Program. Ann. Pharmacother. 37 (2003) 769-774
36. Pai M.P., Rodvold K.A., Schreckenberger P.C., Gonzales R.D., Petrolatti J.M., and Quinn J.P. Risk factors associated with the development of infection with linezolid- and vancomycin-resistant Enterococcus faecium. Clin. Infect. Dis. 35 (2002) 1269-1272
37. Pogue J.M., Paterson D.L., Pasculle A.W., and Potoski B.A. Determination of risk factors associated with isolation of linezolid-resistant strains of vancomycin-resistant Enterococcus. Infect. Contr. Hosp. Epidemiol. 28 (2007) 1382-1388
38. Poppe S., Schaadt R., Sheehan D., Sahm D., Zurenko G., and Shinabarger D. Mutation analysis of Staphylococcus aureus isolates demonstrating trailing linezolid (LZD) endpoints in microdilution MIC assays Abstr. A-088. 106th (2006), American Society for Microbiology, Orlando, FL
39. Rahim S., Pillai S.K., Gold H.S., Venkataraman L., Inglima K., and Press R.A. Linezolid-resistant, vancomycin-resistant Enterococcus faecium infection in patients without prior exposure to linezolid. Clin. Infect. Dis. 36 (2003) E146-E148
40. Ross J.E., Anderegg T.R., Sader H.S., Fritsche T.R., and Jones R.N. Trends in linezolid susceptibility patterns in 2002: report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum Program. Diagn. Microbiol. Infect. Dis. 52 (2005) 53-58
41. Ross J.E., Fritsche T.R., Sader H.S., and Jones R.N. Oxazolidinone susceptibility patterns for 2005: international report from the Zyvox® Annual Appraisal of Potency and Spectrum Study. Int. J. Antimicrob. Agents 29 (2007) 295-301
42. Rubinstein E., Cammarata S., Oliphant T., and Wunderink R. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin. Infect. Dis. 32 (2001) 402-412
43. Rubinstein E., Isturiz R., Standiford H.C., Smith L.G., Oliphant T.H., Cammarata S., Hafkin B., Le V., and Remington J. Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled phase III studies. Antimicrob. Agents Chemother. 47 (2003) 1824-1831
44. Shorr A.F., Kunkel M.J., and Kollef M. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. J. Antimicrob. Chemother. 56 (2005) 923-929
45. Souli M., Sakka V., Galani I., Antoniadou A., Galani L., Siafakas N., Zerva L., Fytrou H., Tsiodras S., and Giamarellou H. Colonisation with vancomycin- and linezolid-resistant Enterococcus faecium in a university hospital: molecular epidemiology and risk factor analysis. Int. J. Antimicrob. Agents 33 (2009) 137-142
46. Spellberg B., Yoo T., and Bayer A.S. Reversal of linezolid-associated cytopenias, but not peripheral neuropathy, by administration of vitamin B6. J. Antimicrob. Chemother. 54 (2004) 832-835
47. Stevens D.L., Herr D., Lampiris H., Hunt J.L., Batts D.H., and Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin. Infect. Dis. 34 (2002) 1481-1490
48. Tenover F.C., Williams P.P., Stocker S., Thompson A., Clark L.A., Limbago B., Carey R.B., Poppe S.M., Shinabarger D., and McGowan Jr. J.E. Accuracy of six antimicrobial susceptibility methods for testing linezolid against staphylococci and enterococci. J. Clin. Microbiol. 45 (2007) 2917-2922
49. Tsiodras S., Gold H.S., Sakoulas G., Eliopoulos G.M., Wennersten C., Venkataraman L., Moellering R.C., and Ferraro M.J. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 358 (2001) 207-208
50. Weigelt J., Itani K., Stevens D., Lau W., Dryden M., and Knirsch C. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob. Agents Chemother. 49 (2005) 2260-2266
51. Wolter N., Smith A.M., Farrell D.J., Schaffner W., Moore M., Whitney C.G., Jorgensen J.H., and Klugman K.P. Novel mechanism of resistance to oxazolidinones, macrolides, and chloramphenicol in ribosomal protein L4 of the pneumococcus. Antimicrob. Agents Chemother. 49 (2005) 3554-3557
52. Woodford N., North S.E., and Ellington M.J. Detecting mutations that confer oxazolidinone resistance in gram-positive bacteria. Methods Mol. Biol. 373 (2007) 103-114
53. Wunderink R.G., Cammarata S.K., Oliphant T.H., and Kollef M.H. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin. Ther. 25 (2003) 980-992
54. Wunderink R.G., Rello J., Cammarata S.K., Croos-Dabrera R.V., and Kollef M.H. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 124 (2003) 1789-1797
55. Zyvox Package Insert A. available at (2008). http://www.pfizer.com/products/rx/rx_product_zyvox.jsp Accessed June 2009